A Phase 4 interventional study of Propranolol and Nicotine Patch in Tobacco Use Disorder, Nicotine Dependence and Cigarette Smoking, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by University of Oklahoma · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing Nicotine Patch in Tobacco Use Disorder — 4 open to participants now, 5 under way, 2 of them phase 3. Nicotine Patch · Tobacco Use Disorder.
Among the 42 studies testing Nicotine Patch in Tobacco Use Disorder, this one is the 30th largest by planned enrollment, is the only one that started in 2024, is one of 14 in phase 4, and was the 40th registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →4 of the 42 studies testing Nicotine Patch in Tobacco Use Disorder are open now, in 4 countries. Recruiting first, the newest first:
Henan Provincial People's Hospital · Sites in China
Ages 18–75 · Men only
Jasper A. Smits · Sites in United States
Ages 18+ · Healthy volunteers
University of Southern California · Sites in Uganda, Zambia
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Nicotine Patch: first FDA approval 1991 (NICODERM CQ). What it is approved for, and how studies give it, is on its page →
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 21 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 8 · Phase 4 14
First in 1999; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 135 across the 42 interventional studies. Of the 35 that completed or were terminated, 21 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 42 have an industry lead sponsor. The 10 most frequent:
University of Oklahoma is the lead sponsor of 432 studies on the registry; 98 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.
University of Oklahoma has 3 studies filed under Tobacco Use Disorder — fewer than ten, so there is no comparison to draw.
3 of the studies testing Nicotine Patch in Tobacco Use Disorder that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT07250230Henan Provincial People's HospitalEffect of Perioperative High-dose Transdermal Nicotine Patch on Pain Sensitivity Among Male Abstinent Tobacco Smokers Undergoing Thoracic Surgery: A Randomized Controlled Pilot Study | 2026-12-31 |
| NCT05587361University of OklahomaBeta-Adrenergic Modulation of Drug Cue Reactivity | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies testing Nicotine Patch in Tobacco Use Disorder, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Cigarette use remains a serious public health problem in the United States and worldwide. Effective pharmacological interventions for smoking cessation exist, but these medications primarily target nicotine withdrawal and smoking reinforcement. The cues and contexts associated with smoking also play an important role in driving smoking behavior, but evidence is extremely mixed whether existing interventions can effectively attenuate smoking urges and behavior in response to these cues and contexts.
In a previous pilot trial, the investigators demonstrated that propranolol suppressed smoking cue reactivity and brain activation across a constellation of brain regions implicated in nicotine dependence. Here, the investigators seek to extend this work by examining effects when the drug is administered in combination with an established treatment targeting withdrawal and reinforcement (i.e., nicotine patch).
Following consent and screening/baseline activities, participants will attend four neuroimaging appointments each lasting approximately 5 hours. Participants will be fitted with a nicotine or placebo patch, fed a standard meal and then administered propranolol or placebo. Participants will complete questionnaires and have their heart rate/blood pressure monitored throughout the visit. During the MRI scan, participants will be asked to complete both resting scans and task-based scans during which participants will view images of smoking and non-smoking objects and scenes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Nicotine Patch Placebo Propranolol
Drug: Placebo Propranolol · Drug: Placebo Patch
Placebo Nicotine Patch Active Propranolol (40 mg, immediate release)
Drug: Propranolol · Drug: Placebo Patch
Active Nicotine Patch (14 mg) Placebo Propranolol
Drug: Nicotine Patch · Drug: Placebo Propranolol
Active Nicotine Patch (14 mg) Active Propranolol (40 mg, immediate release)
Drug: Propranolol · Drug: Nicotine Patch
Propranolol Capsule; 40 mg IR
Nicotine Patch; 14 mg
Placebo Capsule, no active ingredients
Placebo Patch, no active ingredients
Cue-Provoked Craving Ratings
Self-reported smoking urges in response to smoking and non-smoking cues during magnetic resonance imaging (MRI) scan. Scores range from 0 to 10 with higher values indicating increased craving for cigarettes.
Time frame: Approximately 4-5 hours
Blood-Oxygen Level Dependent (BOLD) Activation to Smoking Cues
Blood-Oxygen Level Dependent (BOLD) Contrast (Smoking-Neutral) in Anterior Hippocampus, Amygdala, Dorsal Anterior Insula, Medial Prefrontal Cortex, Posterior Cingulate Cortex and Ventral Striatum
Time frame: Approximately 4-5 hours
Association between Smoking Urge and Brain Activation
Indices of covariation between cue-provoked craving BOLD activation to smoking cues
Time frame: Approximately 4-5 hours
Hippocampus-Amygdala connectivity to smoking cues
Index of connectivity between these brain regions
Time frame: Approximately 4-5 hours
Medial Prefrontal Cortex and Posterior Cingulate Cortex connectivity
Index of connectivity between these brain regions
Time frame: Approximately 4-5 hours
Association between Smoking Urge and Brain Connectivity
Indices of covariation between cue-provoked craving BOLD activation to smoking cues
Time frame: Approximately 4-5 hours
Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.
Of 38 non-industry phase 4 interventional studies under Tobacco Use Disorder, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 28 months is below that.
Counting every sponsor, half of 38 studies reached it within 41 months; a quarter within 30 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Propranolol · Nicotine Patch